Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Compugen Ltd.

Market Cap 191M 0 168M 155M 145M 272M 18.01B 277M 1.86B 722M 8.88B 717M 702M 30.91B P/E 2026 *
-6.97x
P/E 2027 * -7.06x
Enterprise Value 191M 0 168M 155M 145M 272M 18.01B 277M 1.86B 722M 8.88B 717M 702M 30.91B EV / Sales 2026 *
20.3x
EV / Sales 2027 * 11.9x
Free-Float
97.92%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Compugen Ltd.

1 day-2.30%
1 week+2.71%
Current month-25.78%
1 month-24.68%
3 months-6.87%
6 months+23.38%
Current year+28.65%
1 week 575.8
Extreme 575.8
621
1 month 575.8
Extreme 575.8
820.9
Current year 485.2
Extreme 485.2
924
1 year 435
Extreme 435
924
3 years 208.1
Extreme 208.1
1,175
5 years 208.1
Extreme 208.1
2,996
10 years 208.1
Extreme 208.1
6,766
Manager TitleAgeSince
Chief Executive Officer - 2025-09-22
Director of Finance/CFO 42 2024-08-14
Chief Operating Officer 49 2023-12-31
Director TitleAgeSince
Chairman 59 2025-09-22
Director/Board Member 59 2018-06-10
Director/Board Member 70 2018-06-10
Change 5-day change 1-year change 3-year change Capi.($)
-2.30%+2.71% - - 191M
+2.56%+7.12%-7.30%+1.26% 44.45B
-0.79%+6.68%+320.47%+576.78% 36.04B
+0.53%+5.79%+4.15%+54.30% 30.7B
+8.65%+8.93%+17.23%-13.05% 28.59B
+7.60%-1.03%+14.05%+20.82% 23.01B
+0.98%+4.43% - - 14.82B
+8.25%+12.30%+62.80%+128.02% 13.52B
+2.73%+7.16%+11.00%+19.38% 12.98B
+1.67%+3.83%+94.64%+97.33% 12.56B
Average +2.98%+2.88%+64.63%+110.60% 24.07B
Weighted average by Cap. +3.23%+3.11%+71.09%+127.92%

Financials

2026 *2027 *
Net sales 9.41M 0 8.29M 7.65M 7.15M 13.4M 887M 13.65M 91.88M 35.59M 438M 35.35M 34.58M 1.52B 16.05M 0 14.13M 13.03M 12.19M 22.84M 1.51B 23.26M 157M 60.66M 746M 60.25M 58.95M 2.6B
Net income -27.6M -0 -24.3M -22.41M -20.96M -39.27M -2.6B -40M -269M -104M -1.28B -104M -101M -4.46B -28.01M -0 -24.66M -22.75M -21.27M -39.86M -2.64B -40.61M -273M -106M -1.3B -105M -103M -4.53B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
26-06-24 ILA 602.10 -2.30% 5,616
26-06-23 ILA 616.30 +1.85% 11,240
26-06-22 ILA 605.10 +4.44% 15,559
26-06-19 ILA 579.40 -1.41% 357
26-06-18 ILA 587.70 +0.26% 44,246
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.020USD
Average target price
4.600USD
Spread / Average Target
+127.72%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!